MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system.
Identifieur interne : 000250 ( Main/Exploration ); précédent : 000249; suivant : 000251MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system.
Auteurs : J. Puig-Barberà [Espagne] ; A. Natividad-Sancho ; J. Calabuig-Pérez ; J A Lluch-Rodrigo ; E. Pastor-Villalba ; S. Martínez-Úbeda ; S. Pérez-Vilar ; J. Díez-DomingoSource :
- Vaccine [ 1873-2518 ] ; 2013.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (usage thérapeutique), Comorbidité (MeSH), Espagne (MeSH), Femelle (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (épidémiologie), Hospitalisation (statistiques et données numériques), Humains (MeSH), Modèles des risques proportionnels (MeSH), Mâle (MeSH), Polysorbates (usage thérapeutique), Résultat thérapeutique (MeSH), Squalène (usage thérapeutique), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Vaccination (statistiques et données numériques), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (usage thérapeutique), Études de cohortes (MeSH), Études rétrospectives (MeSH).
- MESH :
- immunologie : Vaccins antigrippaux.
- prévention et contrôle : Grippe humaine.
- statistiques et données numériques : Hospitalisation, Vaccination.
- usage thérapeutique : Adjuvants immunologiques, Polysorbates, Squalène, Vaccins antigrippaux.
- épidémiologie : Grippe humaine.
- Comorbidité, Espagne, Femelle, Humains, Modèles des risques proportionnels, Mâle, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Études de cohortes, Études rétrospectives.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (therapeutic use), Aged (MeSH), Aged, 80 and over (MeSH), Cohort Studies (MeSH), Comorbidity (MeSH), Female (MeSH), Hospitalization (statistics & numerical data), Humans (MeSH), Influenza Vaccines (immunology), Influenza Vaccines (therapeutic use), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Male (MeSH), Polysorbates (therapeutic use), Proportional Hazards Models (MeSH), Retrospective Studies (MeSH), Spain (MeSH), Squalene (therapeutic use), Treatment Outcome (MeSH), Vaccination (statistics & numerical data).
- MESH :
- chemical , immunology : Influenza Vaccines.
- chemical , therapeutic use : Adjuvants, Immunologic, Influenza Vaccines, Polysorbates, Squalene.
- geographic : Spain.
- epidemiology : Influenza, Human.
- prevention & control : Influenza, Human.
- statistics & numerical data : Hospitalization, Vaccination.
- Aged, Aged, 80 and over, Cohort Studies, Comorbidity, Female, Humans, Male, Proportional Hazards Models, Retrospective Studies, Treatment Outcome.
Abstract
BACKGROUND
Adjuvanted influenza vaccines offer greater and broader immunogenicity to older adults than conventional vaccines. Studies assessing the comparative effectiveness of adjuvanted influenza vaccines in this age group are lacking.
METHODS
We conducted a retrospective cohort study to estimate the comparative effectiveness of MF59-adjuvanted trivalent influenza vaccine (TIV) and virosomal-TIV for prevention of influenza hospitalization in adults aged ≥65 years. We obtained administrative data on immunization status and influenza hospitalization for the 2010-2011 influenza season. We used Cox regression models to assess comparative effectiveness; crude and adjusted by age, sex, comorbidity, deprivation, type of insurance, and travel time to hospital. We accounted for data clustering at the hospital level by using a multilevel random effects model.
RESULTS
Overall, 373,798 vaccinated subjects were evaluated. There were 40 hospitalizations for influenza among 176,618 subjects, contributing 4,288,109 person-weeks at risk in the virosomal-TIV group, and 37 hospitalizations for influenza among 197,180 subjects, contributing 4,786,360 person-weeks at risk in the MF59-TIV group. The crude hazard ratio (HR) was 0.83 (0.53-1.30), and the adjusted Cox estimated HR of MF59-TIV relative to virosomal-TIV was 0.86 (0.55-1.35). After accounting for data clustering, the HR of influenza hospitalization associated with MF59-TIV relative to virosomal-TIV was 0.94 (0.37-2.38).
CONCLUSION
During the 2010-2011 influenza season, we found no differences in the risk of influenza hospitalization in subjects aged ≥65 years vaccinated with MF59-TIV compared with those vaccinated with virosomal-TIV.
DOI: 10.1016/j.vaccine.2013.05.070
PubMed: 23731629
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system.</title><author><name sortKey="Puig Barbera, J" sort="Puig Barbera, J" uniqKey="Puig Barbera J" first="J" last="Puig-Barberà">J. Puig-Barberà</name><affiliation wicri:level="1"><nlm:affiliation>Área de Investigación en Vacunas, Centro Superior de Investigación en Salud Pública (CSISP), Valencia, Spain. puig_joa@gva.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Área de Investigación en Vacunas, Centro Superior de Investigación en Salud Pública (CSISP), Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Natividad Sancho, A" sort="Natividad Sancho, A" uniqKey="Natividad Sancho A" first="A" last="Natividad-Sancho">A. Natividad-Sancho</name></author><author><name sortKey="Calabuig Perez, J" sort="Calabuig Perez, J" uniqKey="Calabuig Perez J" first="J" last="Calabuig-Pérez">J. Calabuig-Pérez</name></author><author><name sortKey="Lluch Rodrigo, J A" sort="Lluch Rodrigo, J A" uniqKey="Lluch Rodrigo J" first="J A" last="Lluch-Rodrigo">J A Lluch-Rodrigo</name></author><author><name sortKey="Pastor Villalba, E" sort="Pastor Villalba, E" uniqKey="Pastor Villalba E" first="E" last="Pastor-Villalba">E. Pastor-Villalba</name></author><author><name sortKey="Martinez Beda, S" sort="Martinez Beda, S" uniqKey="Martinez Beda S" first="S" last="Martínez-Úbeda">S. Martínez-Úbeda</name></author><author><name sortKey="Perez Vilar, S" sort="Perez Vilar, S" uniqKey="Perez Vilar S" first="S" last="Pérez-Vilar">S. Pérez-Vilar</name></author><author><name sortKey="Diez Domingo, J" sort="Diez Domingo, J" uniqKey="Diez Domingo J" first="J" last="Díez-Domingo">J. Díez-Domingo</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23731629</idno><idno type="pmid">23731629</idno><idno type="doi">10.1016/j.vaccine.2013.05.070</idno><idno type="wicri:Area/Main/Corpus">00242</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00242</idno><idno type="wicri:Area/Main/Curation">000242</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000242</idno><idno type="wicri:Area/Main/Exploration">000242</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system.</title><author><name sortKey="Puig Barbera, J" sort="Puig Barbera, J" uniqKey="Puig Barbera J" first="J" last="Puig-Barberà">J. Puig-Barberà</name><affiliation wicri:level="1"><nlm:affiliation>Área de Investigación en Vacunas, Centro Superior de Investigación en Salud Pública (CSISP), Valencia, Spain. puig_joa@gva.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Área de Investigación en Vacunas, Centro Superior de Investigación en Salud Pública (CSISP), Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Natividad Sancho, A" sort="Natividad Sancho, A" uniqKey="Natividad Sancho A" first="A" last="Natividad-Sancho">A. Natividad-Sancho</name></author><author><name sortKey="Calabuig Perez, J" sort="Calabuig Perez, J" uniqKey="Calabuig Perez J" first="J" last="Calabuig-Pérez">J. Calabuig-Pérez</name></author><author><name sortKey="Lluch Rodrigo, J A" sort="Lluch Rodrigo, J A" uniqKey="Lluch Rodrigo J" first="J A" last="Lluch-Rodrigo">J A Lluch-Rodrigo</name></author><author><name sortKey="Pastor Villalba, E" sort="Pastor Villalba, E" uniqKey="Pastor Villalba E" first="E" last="Pastor-Villalba">E. Pastor-Villalba</name></author><author><name sortKey="Martinez Beda, S" sort="Martinez Beda, S" uniqKey="Martinez Beda S" first="S" last="Martínez-Úbeda">S. Martínez-Úbeda</name></author><author><name sortKey="Perez Vilar, S" sort="Perez Vilar, S" uniqKey="Perez Vilar S" first="S" last="Pérez-Vilar">S. Pérez-Vilar</name></author><author><name sortKey="Diez Domingo, J" sort="Diez Domingo, J" uniqKey="Diez Domingo J" first="J" last="Díez-Domingo">J. Díez-Domingo</name></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (therapeutic use)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Cohort Studies (MeSH)</term><term>Comorbidity (MeSH)</term><term>Female (MeSH)</term><term>Hospitalization (statistics & numerical data)</term><term>Humans (MeSH)</term><term>Influenza Vaccines (immunology)</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Male (MeSH)</term><term>Polysorbates (therapeutic use)</term><term>Proportional Hazards Models (MeSH)</term><term>Retrospective Studies (MeSH)</term><term>Spain (MeSH)</term><term>Squalene (therapeutic use)</term><term>Treatment Outcome (MeSH)</term><term>Vaccination (statistics & numerical data)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (usage thérapeutique)</term><term>Comorbidité (MeSH)</term><term>Espagne (MeSH)</term><term>Femelle (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (épidémiologie)</term><term>Hospitalisation (statistiques et données numériques)</term><term>Humains (MeSH)</term><term>Modèles des risques proportionnels (MeSH)</term><term>Mâle (MeSH)</term><term>Polysorbates (usage thérapeutique)</term><term>Résultat thérapeutique (MeSH)</term><term>Squalène (usage thérapeutique)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Vaccination (statistiques et données numériques)</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins antigrippaux (usage thérapeutique)</term><term>Études de cohortes (MeSH)</term><term>Études rétrospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Influenza Vaccines</term><term>Polysorbates</term><term>Squalene</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Hospitalisation</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Polysorbates</term><term>Squalène</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Cohort Studies</term><term>Comorbidity</term><term>Female</term><term>Humans</term><term>Male</term><term>Proportional Hazards Models</term><term>Retrospective Studies</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Comorbidité</term><term>Espagne</term><term>Femelle</term><term>Humains</term><term>Modèles des risques proportionnels</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études de cohortes</term><term>Études rétrospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Adjuvanted influenza vaccines offer greater and broader immunogenicity to older adults than conventional vaccines. Studies assessing the comparative effectiveness of adjuvanted influenza vaccines in this age group are lacking.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>We conducted a retrospective cohort study to estimate the comparative effectiveness of MF59-adjuvanted trivalent influenza vaccine (TIV) and virosomal-TIV for prevention of influenza hospitalization in adults aged ≥65 years. We obtained administrative data on immunization status and influenza hospitalization for the 2010-2011 influenza season. We used Cox regression models to assess comparative effectiveness; crude and adjusted by age, sex, comorbidity, deprivation, type of insurance, and travel time to hospital. We accounted for data clustering at the hospital level by using a multilevel random effects model.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Overall, 373,798 vaccinated subjects were evaluated. There were 40 hospitalizations for influenza among 176,618 subjects, contributing 4,288,109 person-weeks at risk in the virosomal-TIV group, and 37 hospitalizations for influenza among 197,180 subjects, contributing 4,786,360 person-weeks at risk in the MF59-TIV group. The crude hazard ratio (HR) was 0.83 (0.53-1.30), and the adjusted Cox estimated HR of MF59-TIV relative to virosomal-TIV was 0.86 (0.55-1.35). After accounting for data clustering, the HR of influenza hospitalization associated with MF59-TIV relative to virosomal-TIV was 0.94 (0.37-2.38).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>During the 2010-2011 influenza season, we found no differences in the risk of influenza hospitalization in subjects aged ≥65 years vaccinated with MF59-TIV compared with those vaccinated with virosomal-TIV.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23731629</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2013</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>37</Issue><PubDate><Year>2013</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system.</ArticleTitle><Pagination><MedlinePgn>3995-4002</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2013.05.070</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(13)00685-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Adjuvanted influenza vaccines offer greater and broader immunogenicity to older adults than conventional vaccines. Studies assessing the comparative effectiveness of adjuvanted influenza vaccines in this age group are lacking.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective cohort study to estimate the comparative effectiveness of MF59-adjuvanted trivalent influenza vaccine (TIV) and virosomal-TIV for prevention of influenza hospitalization in adults aged ≥65 years. We obtained administrative data on immunization status and influenza hospitalization for the 2010-2011 influenza season. We used Cox regression models to assess comparative effectiveness; crude and adjusted by age, sex, comorbidity, deprivation, type of insurance, and travel time to hospital. We accounted for data clustering at the hospital level by using a multilevel random effects model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 373,798 vaccinated subjects were evaluated. There were 40 hospitalizations for influenza among 176,618 subjects, contributing 4,288,109 person-weeks at risk in the virosomal-TIV group, and 37 hospitalizations for influenza among 197,180 subjects, contributing 4,786,360 person-weeks at risk in the MF59-TIV group. The crude hazard ratio (HR) was 0.83 (0.53-1.30), and the adjusted Cox estimated HR of MF59-TIV relative to virosomal-TIV was 0.86 (0.55-1.35). After accounting for data clustering, the HR of influenza hospitalization associated with MF59-TIV relative to virosomal-TIV was 0.94 (0.37-2.38).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">During the 2010-2011 influenza season, we found no differences in the risk of influenza hospitalization in subjects aged ≥65 years vaccinated with MF59-TIV compared with those vaccinated with virosomal-TIV.</AbstractText><CopyrightInformation>Copyright © 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Puig-Barberà</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Área de Investigación en Vacunas, Centro Superior de Investigación en Salud Pública (CSISP), Valencia, Spain. puig_joa@gva.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natividad-Sancho</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Calabuig-Pérez</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lluch-Rodrigo</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Pastor-Villalba</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Martínez-Úbeda</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Pérez-Vilar</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Díez-Domingo</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C089950">MF59 oil emulsion</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011136">Polysorbates</NameOfSubstance></Chemical><Chemical><RegistryNumber>7QWM220FJH</RegistryNumber><NameOfSubstance UI="D013185">Squalene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011136" MajorTopicYN="N">Polysorbates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013185" MajorTopicYN="N">Squalene</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aged</Keyword><Keyword MajorTopicYN="N">Cohort studies</Keyword><Keyword MajorTopicYN="N">Comparative effectiveness research</Keyword><Keyword MajorTopicYN="N">Hospitalization</Keyword><Keyword MajorTopicYN="N">Influenza vaccines</Keyword><Keyword MajorTopicYN="N">Subunit</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>03</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>05</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>05</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23731629</ArticleId><ArticleId IdType="pii">S0264-410X(13)00685-3</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.070</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country></list><tree><noCountry><name sortKey="Calabuig Perez, J" sort="Calabuig Perez, J" uniqKey="Calabuig Perez J" first="J" last="Calabuig-Pérez">J. Calabuig-Pérez</name><name sortKey="Diez Domingo, J" sort="Diez Domingo, J" uniqKey="Diez Domingo J" first="J" last="Díez-Domingo">J. Díez-Domingo</name><name sortKey="Lluch Rodrigo, J A" sort="Lluch Rodrigo, J A" uniqKey="Lluch Rodrigo J" first="J A" last="Lluch-Rodrigo">J A Lluch-Rodrigo</name><name sortKey="Martinez Beda, S" sort="Martinez Beda, S" uniqKey="Martinez Beda S" first="S" last="Martínez-Úbeda">S. Martínez-Úbeda</name><name sortKey="Natividad Sancho, A" sort="Natividad Sancho, A" uniqKey="Natividad Sancho A" first="A" last="Natividad-Sancho">A. Natividad-Sancho</name><name sortKey="Pastor Villalba, E" sort="Pastor Villalba, E" uniqKey="Pastor Villalba E" first="E" last="Pastor-Villalba">E. Pastor-Villalba</name><name sortKey="Perez Vilar, S" sort="Perez Vilar, S" uniqKey="Perez Vilar S" first="S" last="Pérez-Vilar">S. Pérez-Vilar</name></noCountry><country name="Espagne"><noRegion><name sortKey="Puig Barbera, J" sort="Puig Barbera, J" uniqKey="Puig Barbera J" first="J" last="Puig-Barberà">J. Puig-Barberà</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000250 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000250 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23731629
|texte= MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23731629" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |